Integrating pharmacogenetic testing into primary care

References

• Kantor ED, Rehm CD, Haas JS, et al. Trends in prescription drug use among adults in the United States from 1999–2012. JAMA. 2015 Nov 03;314(17):1818–1831.
   PubMed Web of Science ®Google Scholar
• U.S. Centers for Disease Control and Prevention. National ambulatory medical care survey: 2010 summary tables. http://wwwcdcgov/nchs/data/ahcd/namcs_summary/2010_namcs_web_tablespdf. 2010;Accessed 2017 Jun 30.
   Google Scholar
• Harada S, Zhou Y, Duncan S, et al. Precision medicine at the university of alabama at birmingham: laying the foundational processes through implementation of genotype-guided antiplatelet therapy. Clin Pharmacol Ther. 2017 Sep;102(3):493–501.
   PubMed Web of Science ®Google Scholar
• Pulley JM, Denny JC, Peterson JF, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project.Clin Pharmacol Ther. 2012 Jul;92(1):87–95.
   PubMed Web of Science ®Google Scholar
• Lynch J, DuVall SL, Berse B, et al. Implementation of pharmacogenetic testing within the veterans health administration from 2011 to 2013. Mil Med. 2016 Oct;181(10):1375–1381.
   PubMed Web of Science ®Google Scholar
• Dunnenberger HM, Crews KR, Hoffman JM, et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol. 2015 Oct;2(55):89–106.
   Google Scholar
• Schuck RN, Marek E, Rogers H, et al. Clinical and regulatory considerations in pharmacogenetic testing. Am J Health Syst Pharm. 2016 Dec 01;73(23):1999–2006.
   PubMed Web of Science ®Google Scholar
• Hess GP, Fonseca E, Scott R, et al. Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders. Genet Res (Camb). 2015;97:e13.
   PubMed Web of Science ®Google Scholar
• Scott SA. Personalizing medicine with clinical pharmacogenetics. Genet Med. 2011 Dec;13(12):987–995.
   PubMed Web of Science ®Google Scholar
• Verbeurgt P, Mamiya T, Oesterheld J. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. Pharmacogenomics. 2014 Apr;15(5):655–665.
   PubMed Web of Science ®Google Scholar
• Van Driest SL, Shi Y, Bowton EA, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther. 2014 Apr;95(4):423–431.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Vicente AE, Lumbreras E, Hernandez JM, et al. Pharmacogenetics and pharmacogenomics as tools in cancer therapy. Drug Metab Pers Ther. 2016 Mar;31(1):25–34.
   PubMedGoogle Scholar
• Manworren RC, Jeffries L, Pantaleao A, et al. Pharmacogenetic testing for analgesic adverse effects: pediatric case series. Clin J Pain. 2016 Feb;32(2):109–115.
   PubMed Web of Science ®Google Scholar
• Agarwal D, Udoji MA, Trescot A. Genetic testing for opioid pain management: a primer. Pain Ther. 2017 Jun;6(1):93–105.
   PubMed Web of Science ®Google Scholar
• Matic M, De Wildt SN, Tibboel D, et al. Analgesia and opioids: a pharmacogenetics shortlist for implementation in clinical practice. Clin Chem. 2017 Jul;63(7):1204–1213.
   PubMed Web of Science ®Google Scholar
• Bousman CA, Forbes M, Jayaram M, et al. Antidepressant prescribing in the precision medicine era: a prescriber’s primer on pharmacogenetic tools. BMC Psychiatry. 2017 Feb 08;17(1):60.
   PubMedGoogle Scholar
• Bousman CA, Hopwood M. Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry. 2016 Jun;3(6):585–590.
   PubMed Web of Science ®Google Scholar
• Eum S, Schneiderhan ME, Brown JT, et al. Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report. BMC Psychiatry. 2017 Jul 03;17(1):238.
   PubMedGoogle Scholar
• Li Y, Wu S, Bai F. Molecular characterization of circulating tumor cells-from bench to bedside. Semin Cell Dev Biol. 2017 Sep 9. pii: S1084-9521(17)30296-3. doi: 10.1016/j.semcdb.2017.09.013. [Epub ahead of print].
   Google Scholar
• O’Flaherty L, Wikman H, Pantel K. Biology and clinical significance of circulating tumor cell subpopulations in lung cancer. Transl Lung Cancer Res. 2017 Aug;6(4):431–443.
   PubMed Web of Science ®Google Scholar
• Mu Z, Benali-Furet N, Uzan G, et al. Detection and characterization of circulating tumor associated cells in metastatic breast cancer. Int J Mol Sci. 2016 Sep 30;17(10).
   Web of Science ®Google Scholar
• Liu W, Yin B, Wang X, et al. Circulating tumor cells in prostate cancer: precision diagnosis and therapy. Oncol Lett. 2017 Aug;14(2):1223–1232.
   PubMed Web of Science ®Google Scholar
• Kaufman AL, Spitz J, Jacobs M, et al. Evidence for clinical implementation of pharmacogenomics in Cardiac Drugs. Mayo Clin Proc. 2015 Jun;90(6):716–729.
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008 Feb 07;358(6):568–579.
   PubMed Web of Science ®Google Scholar
• Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008 Apr 1;46(7):1111–1118.
   PubMed Web of Science ®Google Scholar
• Cargnin S, Jommi C, Canonico PL, et al. Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review. Pharmacogenomics. 2014 May;15(7):963–976.
   PubMed Web of Science ®Google Scholar
• Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the infectious diseases society of America. Clin Infect Dis. 2014 Jan;58(1):e1–34.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. http://wwwaidsinfonihgov/ContentFiles/AdultandAdolescentGLpdf. 2012;Accessed 2017 Jun 08, 2017(Sept 08, 2017(Sept 13.
   Google Scholar
• Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013 Dec 12;369(24):2283–2293.
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of Warfarin. New England Journal of Medicine. 2013 Dec 12;369(24):2294–2303.
   PubMed Web of Science ®Google Scholar
• Verhoef TI, Ragia G, De Boer A, et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med. 2013 Dec 12;369(24):2304–2312.
   PubMed Web of Science ®Google Scholar
• Baker WL, Johnson SG. Pharmacogenetics and oral antithrombotic drugs. Curr Opin Pharmacol. 2016 Apr;27:38–42.
   PubMed Web of Science ®Google Scholar
• Samwald M, Xu H, Blagec K, et al. Incidence of exposure of patients in the united states to multiple drugs for which pharmacogenomic guidelines are available. PLoS One. 2016;11(10):e0164972.
   PubMed Web of Science ®Google Scholar
• Bielinski SJ, Olson JE, Pathak J, et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clin Proc. 2014 Jan;89(1):25–33.
   PubMed Web of Science ®Google Scholar
• Van Der Wouden CH, Cambon-Thomsen A, Cecchin E, et al. Implementing pharmacogenomics in Europe: design and implementation strategy of the Ubiquitous pharmacogenomics consortium. Clin Pharmacol Ther. 2017 Mar;101(3):341–358.
   PubMed Web of Science ®Google Scholar
• Ji Y, Skierka JM, Blommel JH, et al. Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascade. J Mol Diagn. 2016 May;18(3):438–445.
   PubMed Web of Science ®Google Scholar
• Cousin MA, Matey ET, Blackburn PR, et al. Pharmacogenomic findings from clinical whole exome sequencing of diagnostic odyssey patients. Mol Genet Genomic Med. 2017 May;5(3):269–279.
   PubMed Web of Science ®Google Scholar
• Lu M, Lewis CM, Traylor M. Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe. BMC Med Genomics. 2017 Jun 19;10(1):47.
   PubMedGoogle Scholar
• Brewer NT, Defrank JT, Chiu WK, et al. Patients’ understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer. Public Health Genomics. 2014;17(1):43–47.
   PubMed Web of Science ®Google Scholar
• Hamilton JG, Abdiwahab E, Edwards HM, et al. Primary care providers’ cancer genetic testing-related knowledge, attitudes, and communication behaviors: A systematic review and research agenda. J Gen Intern Med. 2017 Mar;32(3):315–324.
   PubMed Web of Science ®Google Scholar
• Just KS, Steffens M, Swen JJ, et al. Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx). Eur J Clin Pharmacol. 2017 Jul 02.
   PubMed Web of Science ®Google Scholar
• Elewa H, Alkhiyami D, Alsahan D, et al. A survey on the awareness and attitude of pharmacists and doctors towards the application of pharmacogenomics and its challenges in Qatar. J Eval Clin Pract. 2015 Aug;21(4):703–709.
   PubMed Web of Science ®Google Scholar
• Stanek EJ, Sanders CL, Taber KA, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther. 2012 Mar;91(3):450–458.
   PubMed Web of Science ®Google Scholar
• Nickola TJ, Green JS, Harralson AF, et al. The current and future state of pharmacogenomics medical education in the USA.Pharmacogenomics. 2012 Sep;13(12):1419–1425.
   PubMed Web of Science ®Google Scholar
• Green JS, O’Brien TJ, Chiappinelli VA, et al. Pharmacogenomics instruction in US and Canadian medical schools: implications for personalized medicine. Pharmacogenomics. 2010 Sep;11(9):1331–1340.
   PubMed Web of Science ®Google Scholar
• Rohrer Vitek CR, Abul-Husn NS, Connolly JJ, et al. Healthcare provider education to support integration of pharmacogenomics in practice: the eMERGE Network experience. Pharmacogenomics. 2017 Jul;18(10):1013–1025.
   PubMed Web of Science ®Google Scholar
• Rao US, Mayhew SL, Rao PS. Strategies for implementation of an effective pharmacogenomics program in pharmacy education. Pharmacogenomics. 2015 Jul;16(8):905–911.
   PubMed Web of Science ®Google Scholar
• Kuo GM, Lee KC, Ma JD. Implementation and outcomes of a live continuing education program on pharmacogenomics. Pharmacogenomics. 2013 Jun;14(8):885–895.
   PubMed Web of Science ®Google Scholar
• Weitzel KW, Aquilante CL, Johnson S, et al. Educational strategies to enable expansion of pharmacogenomics-based care. Am J Health Syst Pharm. 2016 Dec 01;73(23):1986–1998.
   PubMed Web of Science ®Google Scholar
• Hertz DL, Luzum JA, Pasternak AL, et al. Institutional profile of pharmacogenetics within university of michigan college of pharmacy. Pharmacogenomics. 2017 Jul 26.
   Web of Science ®Google Scholar
• Nickola TJ, Munson AM. Pharmacogenomics primer course for first professional year pharmacy students. Pharmacogenomics. 2014 Jan;15(1):39–48.
   PubMed Web of Science ®Google Scholar
• Brazeau DA, Brazeau GA. A required course in human genomics, pharmacogenomics, and bioinformatics. Am J Pharm Educ. 2006 Dec 15;70(6):125.
   PubMed Web of Science ®Google Scholar
• Adams SM, Anderson KB, Coons JC, et al. Advancing pharmacogenomics education in the core pharmd curriculum through student personal genomic testing. Am J Pharm Educ. 2016 Feb 25;80(1):3.
   PubMed Web of Science ®Google Scholar
• Remsberg CM, Bray BS, Wright SK, et al. Design, implementation, and assessment approaches within a pharmacogenomics course. Am J Pharm Educ. 2017 Feb 25;81(1):11.
   PubMed Web of Science ®Google Scholar
• Haidar CE, Hoffman JM, Gammal RS, et al. Development of a postgraduate year 2 pharmacy residency in clinical pharmacogenetics. Am J Health Syst Pharm. 2017 Mar 15;74(6):409–415.
   PubMed Web of Science ®Google Scholar
• Krau SD. Cytochrome p450 part 2: what nurses need to know about the cytochrome p450 family systems. Nurs Clin North Am. 2013 Dec;48(4):681–696.
   PubMed Web of Science ®Google Scholar
• Brennan KS. Clinical implications of pharmacogenetic and microarray testing for advanced practice nurses. J Am Assoc Nurse Pract. 2015 May;27(5):246–255.
   PubMed Web of Science ®Google Scholar
• Dawes M, Aloise MN, Ang JS, et al. Introducing pharmacogenetic testing with clinical decision support into primary care: a feasibility study. CMAJ Open. 2016 Jul-Sep;4(3):E528–e534.
   PubMedGoogle Scholar
• Haga SB. Educating patients and providers through comprehensive pharmacogenetic test reports. Pharmacogenomics. 2017 Jul;18(11):1047–1050.
   PubMed Web of Science ®Google Scholar
• Bousman CA, Jaksa P, Pantelis C. Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting. Pharmacogenet Genomics. 2017 Nov;27(11):387-393. doi: 10.1097/FPC.0000000000000303.
   Web of Science ®Google Scholar
• De Leon J, Susce MT, Johnson M, et al. DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping. CNS Spectr. 2009 Jan;14(1):19–34.
   PubMed Web of Science ®Google Scholar
• Arbitrio M, Di Martino MT, Scionti F, et al. DMET (Drug metabolism enzymes and transporters): a pharmacogenomic platform for precision medicine. Oncotarget. 2016 Aug 16;7(33):54028–54050.
   PubMed Web of Science ®Google Scholar
• Han SM, Park J, Lee JH, et al. Targeted next-generation sequencing for comprehensive genetic profiling of pharmacogenes. Clin Pharmacol Ther. 2017 Mar;101(3):396–405.
   PubMed Web of Science ®Google Scholar
• Desmond A, Kurian AW, Gabree M, et al. Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol. 2015 Oct;1(7):943–951.
   PubMed Web of Science ®Google Scholar
• Giri AK, Khan NM, Basu A, et al. Pharmacogenetic landscape of clopidogrel in north Indians suggest distinct interpopulation differences in allele frequencies. Pharmacogenomics. 2014 Apr;15(5):643–653.
   PubMed Web of Science ®Google Scholar
• Kozyra M, Ingelman-Sundberg M, Lauschke VM. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med. 2017 Jan;19(1):20–29.
   PubMed Web of Science ®Google Scholar
• Mizzi C, Dalabira E, Kumuthini J, et al. A European spectrum of pharmacogenomic biomarkers: implications for clinical pharmacogenomics. PLoS One. 2016;11(9):e0162866.
   PubMed Web of Science ®Google Scholar
• Ricker C, Culver JO, Lowstuter K, et al. Increased yield of actionable mutations using multi-gene panels to assess hereditary cancer susceptibility in an ethnically diverse clinical cohort. Cancer Genet. 2016 Apr;209(4):130–137.
   PubMed Web of Science ®Google Scholar
• Slavin TP, Niell-Swiller M, Solomon I, et al. Clinical application of multigene panels: challenges of next-generation counseling and cancer risk management. Front Oncol. 2015;5:208.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Discussion paper on laboratory developed tests (LDTs). https://wwwfdagov/downloads/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/LaboratoryDevelopedTests/UCM536965pdf. 2017;Acccessed 2017 Jun 17.
   Google Scholar
• U.S. Department of Health and Human Services, U.S. Food and Drug Administration, Center for Devices and Radiological Health, et al. Draft guidance for industry, food and drug administration staff, and clinical laboratories: framework for regulatory oversight of laboratory developed tests (LDTs). http://wwwfdagov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM416685pdf. 2014;Acccessed 2016 Mar 29.
   Google Scholar
• Levy KD, Pratt VM, Skaar TC, et al. FDA’s draft guidance on laboratory-developed tests increases clinical and economic risk to adoption of pharmacogenetic testing. J Clin Pharmacol. 2015 Jul;55(7):725–727.
   PubMed Web of Science ®Google Scholar
• Hillebrenner E, Litwack E, Bradley P, et al. FDA oversight of laboratory-developed tests will facilitate adoption of pharmacogenetic testing into routine clinical care. J Clin Pharmacol. 2015 Jul;55(7):728–730.
   PubMed Web of Science ®Google Scholar
• Conrado DJ, Rogers HL, Zineh I, et al. Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels. Pharmacogenomics. 2013 Jan;14(2):215–223.
   PubMed Web of Science ®Google Scholar
• De Leon J, Spina E. What is needed to incorporate clinical pharmacogenetic tests into the practice of psychopharmacotherapy? Expert Rev Clin Pharmacol. 2016;9(3):351–354.
   PubMed Web of Science ®Google Scholar
• Klein RD. Reimbursement in molecular pathology: bringing genomic medicine to patients. Clin Chem. 2015 Jan;61(1):136–138.
   PubMed Web of Science ®Google Scholar
• Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J. 2017 Jun 13.
   PubMed Web of Science ®Google Scholar
• Berm EJ, Looff M, Wilffert B, et al. Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature. PLoS One. 2016;11(1):e0146262.
   PubMed Web of Science ®Google Scholar
• Ruiz-Iruela C, Padulles-Zamora N, Podzamczer-Palter D, et al. HLA-B*57: 01 genotyping in the prevention of hypersensitivity to abacavir: 5 years of experience. Pharmacogenet Genomics. 2016 Aug;26(8):390–396.
   PubMed Web of Science ®Google Scholar
• Trosman JR, Weldon CB, Douglas MP, et al. Payer coverage for hereditary cancer panels: barriers, opportunities, and implications for the precision medicine initiative. J Natl Compr Canc Netw. 2017 Feb;15(2):219–228.
   PubMed Web of Science ®Google Scholar
• Rosenblat JD, Lee Y, McIntyre RS. Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies. J Clin Psychiatry. 2017 Jun;78(6):720–729.
   PubMed Web of Science ®Google Scholar
• Geenen JW, Baranova EV, Asselbergs FW, et al. Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs. Pharmacogenomics. 2017 Jul 26.
   PubMed Web of Science ®Google Scholar
• Moretti ME, Lato DF, Berger H, et al. A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events. Pharmacogenomics J. 2017 Jul 11.
   PubMedGoogle Scholar
• Marshall DA, Gonzalez JM, Johnson FR, et al. What are people willing to pay for whole-genome sequencing information, and who decides what they receive? Genet Med. 2016 Dec;18(12):1295–1302.
   PubMed Web of Science ®Google Scholar
• Lin PJ, Cangelosi MJ, Lee DW, et al. Willingness to pay for diagnostic technologies: a review of the contingent valuation literature. Value Health. 2013 Jul-Aug;16(5):797–805.
   PubMed Web of Science ®Google Scholar
• Tubeuf S, Willis TA, Potrata B, et al. Willingness to pay for genetic testing for inherited retinal disease. Eur J Hum Genet. 2015 Mar;23(3):285–291.
   PubMed Web of Science ®Google Scholar
• Kopits IM, Chen C, Roberts JS, et al. Willingness to pay for genetic testing for Alzheimer’s disease: a measure of personal utility. Genet Test Mol Biomarkers. 2011 Dec;15(12):871–875.
   PubMed Web of Science ®Google Scholar
• Mills R, Voora D, Peyser B, et al. Delivering pharmacogenetic testing in a primary care setting. Pharmgenomics Pers Med. 2013;6:105–112.
   PubMedGoogle Scholar
• Committee Opinion No: 693. Counseling about genetic testing and communication of genetic test results. Obstet Gynecol. 2017 Apr;129(4):e96–e101.
   PubMed Web of Science ®Google Scholar
• Walden LM, Brandl EJ, Changasi A, et al. Physicians’ opinions following pharmacogenetic testing for psychotropic medication. Psychiatry Res. 2015 Oct 30;229(3):913–918.
   PubMed Web of Science ®Google Scholar
• Thompson C, Steven PH, Catriona H. Psychiatrist attitudes towards pharmacogenetic testing, direct-to-consumer genetic testing, and integrating genetic counseling into psychiatric patient care. Psychiatry Res. 2015 Mar 30;226(1):68–72.
   PubMed Web of Science ®Google Scholar
• Larson EA, Wilke RA. Integration of genomics in primary care. Am J Med. 2015 Nov;128(11):1251.e1–5.
   Web of Science ®Google Scholar
• Williams EC, Young JP, Achtmeyer CE, et al. Primary care providers’ interest in using a genetic test to guide alcohol use disorder treatment. J Subst Abuse Treat. 2016;70:14–20.
   PubMed Web of Science ®Google Scholar
• Fagerness J, Fonseca E, Hess GP, et al. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. Am J Manag Care. 2014 May;20(5):e146–56.
   PubMed Web of Science ®Google Scholar
• Charland SL, Agatep BC, Herrera V, et al. Providing patients with pharmacogenetic test results affects adherence to statin therapy: results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial. Pharmacogenomics J. 2014 Aug 27.
   PubMed Web of Science ®Google Scholar
• Messner DA, Al Naber J, Koay P, et al. Barriers to clinical adoption of next generation sequencing: perspectives of a policy delphi panel. Appl Transl Genom. 2016;10:19–24.
   PubMed Web of Science ®Google Scholar
• Marcus RK, Geurts JL, Grzybowski JA, et al. Challenges to clinical utilization of hereditary cancer gene panel testing: perspectives from the front lines. Fam Cancer. 2015 Dec;14(4):641–649.
   PubMed Web of Science ®Google Scholar
• Peterson JF, Field JR, Unertl KM, et al. Physician response to implementation of genotype-tailored antiplatelet therapy. Clin Pharmacol Ther. 2016 Jul;100(1):67–74.
   PubMed Web of Science ®Google Scholar
• Desai NR, Canestaro WJ, Kyrychenko P, et al. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention. Circulation Cardiovascular Quality and Outcomes. 2013 Nov 1;6(6):694–699.
   PubMed Web of Science ®Google Scholar
• Caraballo PJ, Bielinski SJ, St Sauver JL, et al. Electronic medical record-integrated pharmacogenomics and related clinical decision support concepts. Clin Pharmacol Ther. 2017 Aug;102(2):254–264.
   PubMed Web of Science ®Google Scholar
• Alanazi A. Incorporating pharmacogenomics into health information technology, electronic health record and decision support system: an overview. J Med Syst. 2017 Feb;41(2):19.
   PubMed Web of Science ®Google Scholar
• Heale BSE, Khalifa A, Stone BL, et al. Physicians’ pharmacogenomics information needs and seeking behavior: a study with case vignettes. BMC Med Inform Decis Mak. 2017 Aug 01;17(1):113.
   PubMedGoogle Scholar
• Hinderer M, Boeker M, Wagner SA, et al. Integrating clinical decision support systems for pharmacogenomic testing into clinical routine - a scoping review of designs of user-system interactions in recent system development. BMC Med Inform Decis Mak. 2017 Jun 06;17(1):81.
   PubMedGoogle Scholar
• Melton BL, Zillich AJ, Saleem J, et al. Iterative development and evaluation of a pharmacogenomic-guided clinical decision support system for warfarin dosing. Appl Clin Inform. 2016 Nov 23;7(4):1088–1106.
   PubMed Web of Science ®Google Scholar
• Nishimura AA, Shirts BH, Salama J, et al. Physician perspectives of CYP2C19 and clopidogrel drug-gene interaction active clinical decision support alerts. Int J Med Inform. 2016;86:117–125.
   PubMed Web of Science ®Google Scholar
• Devine EB, Lee CJ, Overby CL, et al. Usability evaluation of pharmacogenomics clinical decision support aids and clinical knowledge resources in a computerized provider order entry system: A mixed methods approach. Int J Med Inform. 2014 Jul;83(7):473–483.
   PubMed Web of Science ®Google Scholar
• Hicks JK, Stowe D, Willner MA, et al. Implementation of clinical pharmacogenomics within a large health system: from electronic health record decision support to consultation services. Pharmacotherapy. 2016 Aug;36(8):940–948.
   PubMed Web of Science ®Google Scholar
• Nutescu EA, Drozda K, Bress AP, et al. Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy. 2013 Nov;33(11):1156–1164.
   PubMed Web of Science ®Google Scholar
• Blagec K, Romagnoli KM, Boyce RD, et al. Examining perceptions of the usefulness and usability of a mobile-based system for pharmacogenomics clinical decision support: a mixed methods study. PeerJ. 2016;4:e1671.
   PubMed Web of Science ®Google Scholar
• Ehmann F, Caneva L, Prasad K, et al. Pharmacogenomic information in drug labels: european medicines agency perspective. Pharmacogenomics J. 2015 Jun;15(3):201–210.
   PubMed Web of Science ®Google Scholar
• Vivot A, Boutron I, Ravaud P, et al. Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs. Genet Med. 2015 Sep;17(9):733–738.
   PubMed Web of Science ®Google Scholar
• Haga SB, Burke W, Ginsburg GS, et al. Primary care physicians’ knowledge of and experience with pharmacogenetic testing.Clin Genet. 2012 Oct;82(4):388–394.
   PubMed Web of Science ®Google Scholar
• Tutton R. Pharmacogenomic biomarkers in drug labels: what do they tell us? Pharmacogenomics. 2014 Feb;15(3):297–304.
   PubMed Web of Science ®Google Scholar
• Caudle KE, Gammal RS, Whirl-Carrillo M, et al. Evidence and resources to implement pharmacogenetic knowledge for precision medicine. Am J Health Syst Pharm. 2016 Dec 01;73(23):1977–1985.
   PubMed Web of Science ®Google Scholar
• Hoffman JM, Dunnenberger HM, Kevin Hicks J, et al. Developing knowledge resources to support precision medicine: principles from the clinical pharmacogenetics implementation consortium (CPIC). J Am Med Inform Assoc. 2016 Jul;23(4):796–801.
   PubMed Web of Science ®Google Scholar
• Aminkeng F, Ross CJ, Rassekh SR, et al. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 2016 Sep;82(3):683–695.
   PubMed Web of Science ®Google Scholar
• Lee JW, Pussegoda K, Rassekh SR, et al. Clinical practice recommendations for the management and prevention of cisplatin-induced hearing loss using pharmacogenetic markers. Ther Drug Monit. 2016 Aug;38(4):423–431.
   PubMed Web of Science ®Google Scholar
• Clinical Pharmacogenetic Implementation Consortium. Dosing Guidelines. [cited 2017 Sep 1]. https://www.pharmgkb.org/guidelines. 2017.
   Google Scholar
• Zhang G, Zhang Y, Ling Y, et al. Web resources for pharmacogenomics. Genomics Proteomics Bioinformatics. 2015 Feb;13(1):51–54.
   PubMed Web of Science ®Google Scholar
• Tarn DM, Paterniti DA, Kravitz RL, et al. How much time does it take to prescribe a new medication? Patient Educ Couns. 2008 Aug;72(2):311–319.
   PubMed Web of Science ®Google Scholar
• Almomani B, Hawwa AF, Goodfellow NA, et al. Pharmacogenetics and the print media: what is the public told? BMC Med Genet. 2015 May;09(16):32.
   Google Scholar
• Mills R, Ensinger M, Callanan N, et al. Development and Initial Assessment of a Patient Education Video about Pharmacogenetics. J Pers Med. 2017 May 25;7(2).
   PubMed Web of Science ®Google Scholar
• Sukasem C, Chantratita W. A success story in pharmacogenomics: genetic ID card for SJS/TEN. Pharmacogenomics. 2016 Apr;17(5):455–458.
   PubMed Web of Science ®Google Scholar
• World Anti-doping Agency. Athlete biological passport. [cited 2017 Sep 1]. https://www.wada-ama.org/en/athlete-biological-passport.
   Google Scholar
• Mills R, Haga SB. Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists. Pharmacogenomics. 2013 Jun;14(8):957–968.
   PubMed Web of Science ®Google Scholar
• Crews KR, Cross SJ, McCormick JN, et al. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm. 2011 Jan 15;68(2):143–150.
   PubMed Web of Science ®Google Scholar
• Walko C, Kiel PJ, Kolesar J. Precision medicine in oncology: new practice models and roles for oncology pharmacists. Am J Health Syst Pharm. 2016 Dec 01;73(23):1935–1942.
   PubMed Web of Science ®Google Scholar
• Haga SB, Moaddeb J, Mills R, et al. Incorporation of pharmacogenetic testing into medication therapy management. Pharmacogenomics. 2015 Nov;16(17):1931–1941.
   PubMed Web of Science ®Google Scholar
• Johnson SG, Shaw PB, Delate T, et al. Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system. Pharm Pract (Granada). 2017;Apr-Jun;15(2):946.
   Google Scholar
• Zierhut HA, Campbell CA, Mitchell AG, et al. Collaborative counseling considerations for pharmacogenomic tests. Pharmacotherapy. 2017 Sep;37(9):990-999. doi: 10.1002/phar.1980. Epub 2017 Aug 7.
   Web of Science ®Google Scholar
• Dunnenberger HM, Biszewski M, Bell GC, et al. Implementation of a multidisciplinary pharmacogenomics clinic in a community health system. Am J Health Syst Pharm. 2016 Dec 01;73(23):1956–1966.
   PubMed Web of Science ®Google Scholar
• Pierson RC, Gufford BT, Desta Z, et al. Clinical and educational impact of pharmacogenomics testing: a case series from the INGENIOUS trial. Pharmacogenomics. 2017 Jun;18(9):835–841.
   PubMed Web of Science ®Google Scholar
• Stack G. Pathology consultation on warfarin pharmacogenetic testing. Am J Clin Pathol. 2011 Jan;135(1):13–19.
   PubMed Web of Science ®Google Scholar
• Russell Teagarden J, Stanek EJ. On pharmacogenomics in pharmacy benefit management. Pharmacotherapy. 2012 Feb;32(2):103–111.
   PubMed Web of Science ®Google Scholar
• Topol EJ. Pharmacy benefit managers, pharmacies, and pharmacogenomic testing: prescription for progress? Sci Transl Med. 2010 Aug 11;2(44):44cm22.
   PubMed Web of Science ®Google Scholar
• Moaddeb J, Mills R, Haga SB. Community pharmacists’ experience with pharmacogenetic testing. J Am Pharm Assoc (2003). 2015 Nov-Dec;55(6):587–594.
   PubMed Web of Science ®Google Scholar
• O’Connor SK, Ferreri SP, Michaels NM, et al. Making pharmacogenetic testing a reality in a community pharmacy. J Am Pharm Assoc. 2012 Nov-Dec;52(6):e259–65.
   Google Scholar
• Ferreri SP, Greco AJ, Michaels NM, et al. Implementation of a pharmacogenomics service in a community pharmacy. J Am Pharm Assoc. 2014 Mar-Apr;54(2):172–180.
   Google Scholar
• Kisor DF, Bright DR, Conaway M, et al. Pharmacogenetics in the community pharmacy: thienopyridine selection post-coronary artery stent placement. J Pharm Pract. 2014 Feb 13;27(4):416–419.
   PubMedGoogle Scholar
• US Food and Drug Administration. Letters to Industry. [cited 2017 Sep 1]. https://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/ucm111104.htm. 2017.
   Google Scholar